Allspring Global Investments Holdings LLC decreased its holdings in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 25.0% during the fourth quarter, according to its most recent filing with the ...

At the Advances in Genome Biology and Technology, AGBT, General Meeting, 10x Genomics (TXG) announced a series of new product innovations to ...

Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use.

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...